# Chronic Urticaria Treatment Algorithm
## Based on AAAAI/ACAAI JTFPP Systematic Reviews (2024-2025)

---

## ALGORITHM OVERVIEW

```
┌─────────────────────────────────────────────────────────────────────────────┐
│                    CHRONIC URTICARIA MANAGEMENT ALGORITHM                   │
│                Based on 2024-2025 JTFPP Systematic Reviews                  │
└─────────────────────────────────────────────────────────────────────────────┘

┌─────────────────────────────────────────────────────────────────────────────┐
│ STEP 1: FIRST-LINE                                                          │
│ ═══════════════════                                                         │
│ Second-generation H1-antihistamine (standard dose)                          │
│ • Cetirizine, loratadine, fexofenadine, etc.                               │
│ • Assess response at 2-4 weeks                                              │
│                                                                             │
│ If INADEQUATE ↓                                                             │
└─────────────────────────────────────────────────────────────────────────────┘
                                    │
                                    ▼
┌─────────────────────────────────────────────────────────────────────────────┐
│ STEP 2: UPDOSE ANTIHISTAMINE                                                │
│ ═════════════════════════════                                               │
│ Increase to 4× standard dose (guideline recommendation)                     │
│ • Example: Cetirizine 10mg QID (40mg/day)                                  │
│ • Assess response at 2-4 weeks                                              │
│                                                                             │
│ If INADEQUATE ↓                                                             │
└─────────────────────────────────────────────────────────────────────────────┘
                                    │
                                    ▼
┌─────────────────────────────────────────────────────────────────────────────┐
│ STEP 2B: ADD-ON OPTIONS (LIMITED EVIDENCE)                                  │
│ ══════════════════════════════════════════                                  │
│                                                                             │
│ ┌─────────────────────────────────────────────────────────────────────┐    │
│ │ LTRAs (e.g., montelukast)                                           │    │
│ │ • MD -5.04 on UAS7 (BELOW MID of 10) [Rayner 2024]                  │    │
│ │ • "Small, potentially patient-unimportant" benefit                  │    │
│ │ • NNH 161 for neuropsychiatric AEs (FDA boxed warning)              │    │
│ │ • CRITICAL GAP: No comparison to 4× AH alone                        │    │
│ │ ⚠️ Requires informed consent and counseling                         │    │
│ └─────────────────────────────────────────────────────────────────────┘    │
│                                                                             │
│ If INADEQUATE or PREFER TO SKIP → Proceed to Step 3                        │
└─────────────────────────────────────────────────────────────────────────────┘
                                    │
                                    ▼
┌─────────────────────────────────────────────────────────────────────────────┐
│ STEP 3: BIOLOGIC THERAPY                                                    │
│ ═════════════════════════                                                   │
│                                                                             │
│ ╔═══════════════════════════════════════════════════════════════════════╗  │
│ ║ FIRST CHOICE: OMALIZUMAB 300mg Q4W                                    ║  │
│ ║ [Chu AWL 2025 NMA]                                                    ║  │
│ ║ • Urticaria activity: MD -8.37 (HIGH certainty)                       ║  │
│ ║ • Angioedema: +8.75% more free weeks (HIGH certainty)                 ║  │
│ ║ • Quality of life: MD -12.68 (HIGH certainty)                         ║  │
│ ║ • Safety: No increase in serious AEs (HIGH certainty)                 ║  │
│ ║ • Route: SC injection, can self-administer                            ║  │
│ ║ • Comorbidity benefits: Asthma, food allergies                        ║  │
│ ╚═══════════════════════════════════════════════════════════════════════╝  │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ ALTERNATIVE: REMIBRUTINIB (where available)                           │  │
│ │ • Urticaria activity: MD -7.65 (HIGH certainty)                       │  │
│ │ • Angioedema: +15.00% more free weeks (HIGH certainty)                │  │
│ │ • Quality of life: MD -11.65 (HIGH certainty)                         │  │
│ │ • Safety: Less certain (LOW certainty for AE profile)                 │  │
│ │ • Route: ORAL — advantage for needle-phobic patients                  │  │
│ │ • ⚠️ Less long-term safety data than omalizumab                       │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ ALTERNATIVE: DUPILUMAB (for type 2 comorbidities)                     │  │
│ │ • Urticaria activity: MD -6.01 (MODERATE certainty)                   │  │
│ │ • Angioedema: ❌ NO DATA — avoid if prominent angioedema              │  │
│ │ • Quality of life: MD -9.73 (LOW certainty)                           │  │
│ │ • Safety: HIGH certainty for low discontinuation                      │  │
│ │ • Route: SC injection, can self-administer                            │  │
│ │ • PREFERRED if: Comorbid atopic dermatitis, CRSwNP                    │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
│                                                                             │
│ Assess response at 4-6 months                                               │
│ If INADEQUATE ↓                                                             │
└─────────────────────────────────────────────────────────────────────────────┘
                                    │
                                    ▼
┌─────────────────────────────────────────────────────────────────────────────┐
│ STEP 4: BIOLOGIC OPTIMIZATION / ESCALATION                                  │
│ ═══════════════════════════════════════════                                 │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ OMALIZUMAB UPDOSING                                                   │  │
│ │ • 300mg Q2W or 450-600mg Q4W                                          │  │
│ │ • ~69% of standard-dose non-responders may respond                    │  │
│ │ • Based on case series data (no RCTs for comparative efficacy)        │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
│                                                                             │
│ If still INADEQUATE ↓                                                       │
└─────────────────────────────────────────────────────────────────────────────┘
                                    │
                                    ▼
┌─────────────────────────────────────────────────────────────────────────────┐
│ STEP 5: IMMUNOSUPPRESSANTS (USE WITH CAUTION)                               │
│ ══════════════════════════════════════════════                              │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ CYCLOSPORINE [Chu AWL 2025 NMA]                                       │  │
│ │ • Urticaria activity: MD -10.18 (LOW certainty)                       │  │
│ │ • ⚠️ MAY BE MOST HARMFUL: +21% more AEs (LOW certainty)               │  │
│ │ • REQUIRES MONITORING: BP, renal function, lipids Q4-8 weeks          │  │
│ │ • Plan for short-term use (3-6 months) if possible                    │  │
│ │ • Reserve for truly refractory cases                                  │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ OTHER IMMUNOMODULATORS (VERY UNCERTAIN EVIDENCE)                      │  │
│ │ • Mycophenolate: MD -15.01 (VERY LOW, non-RCT data)                   │  │
│ │ • Sulfasalazine: MD -10.65 (VERY LOW, non-RCT data)                   │  │
│ │ • Azathioprine: MD -8.07 (LOW certainty)                              │  │
│ │ • Hydroxychloroquine: MD -5.98 (LOW certainty)                        │  │
│ │ • Consider in resource-limited settings or when biologics unavailable │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
│                                                                             │
│ Consider clinical trial enrollment for truly refractory cases               │
└─────────────────────────────────────────────────────────────────────────────┘

═══════════════════════════════════════════════════════════════════════════════
                              ADJUNCTIVE MANAGEMENT
═══════════════════════════════════════════════════════════════════════════════

┌─────────────────────────────────────────────────────────────────────────────┐
│ FOR ACUTE FLARES [Chu X 2024]                                               │
│ ═════════════════════════════                                               │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ SHORT-COURSE SYSTEMIC CORTICOSTEROIDS                                 │  │
│ │ • Duration: <1 week                                                   │  │
│ │ • Example: Prednisone 40mg daily × 5 days                            │  │
│ │                                                                       │  │
│ │ PATIENT SELECTION:                                                    │  │
│ │ ┌─────────────────────────────────────────────────────────────────┐  │  │
│ │ │ Antihistamine-REFRACTORY: NNT = 7 ✓ Meaningful benefit         │  │  │
│ │ │ Antihistamine-RESPONSIVE: NNT = 45 ✗ Minimal benefit           │  │  │
│ │ └─────────────────────────────────────────────────────────────────┘  │  │
│ │                                                                       │  │
│ │ RISKS: NNH = 9 (~15% increased AE risk)                              │  │
│ │ NOT disease-modifying — for acute symptom relief only                │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
└─────────────────────────────────────────────────────────────────────────────┘

┌─────────────────────────────────────────────────────────────────────────────┐
│ FOR LOCALIZED URTICARIA [Chu AWL 2024]                                      │
│ ══════════════════════════════════════                                      │
│                                                                             │
│ ┌───────────────────────────────────────────────────────────────────────┐  │
│ │ TOPICAL CORTICOSTEROIDS                                               │  │
│ │ • Wheal size: ~50% reduction (LOW certainty)                          │  │
│ │ • Itch: Very uncertain effect                                         │  │
│ │ • Safety: No difference in AEs (HIGH certainty)                       │  │
│ │                                                                       │  │
│ │ APPROPRIATE FOR:                                                      │  │
│ │ • Highly localized urticaria                                          │  │
│ │ • Chronic inducible urticaria (dermographism, pressure urticaria)     │  │
│ │ • Predictable trigger areas (bra lines, waistband)                    │  │
│ │                                                                       │  │
│ │ LIMITATIONS:                                                          │  │
│ │ • Impractical for widespread/migratory hives                         │  │
│ │ • Risk of skin atrophy with prolonged use                            │  │
│ │ • Systemic AH more practical for diffuse disease                     │  │
│ └───────────────────────────────────────────────────────────────────────┘  │
└─────────────────────────────────────────────────────────────────────────────┘

═══════════════════════════════════════════════════════════════════════════════
                              TREATMENT FAILURES
═══════════════════════════════════════════════════════════════════════════════

┌─────────────────────────────────────────────────────────────────────────────┐
│ DRUGS THAT FAILED FOR CHRONIC URTICARIA                                     │
│ ═══════════════════════════════════════                                     │
│                                                                             │
│ • Ligelizumab — Development discontinued (PEARL trials: no superiority)     │
│ • Benralizumab — ARROYO trial negative (anti-IL-5 doesn't work for CU)     │
│ • Tezepelumab — INCEPTION trial: limited efficacy (anti-TSLP)              │
│ • Quilizumab — QUAIL trial negative                                         │
│ • Canakinumab — URTICANA trial: no effect (MD 0.02)                        │
│ • Rilonacept — Failed for cold urticaria                                    │
│                                                                             │
│ PATHOPHYSIOLOGY LESSON:                                                     │
│ Anti-IL-5 and anti-TSLP work for type 2 airway inflammation but NOT for    │
│ skin diseases. Urticaria is driven by IgE-mast cell axis and IL-4/IL-13.   │
└─────────────────────────────────────────────────────────────────────────────┘

═══════════════════════════════════════════════════════════════════════════════
                            EMERGING THERAPIES
═══════════════════════════════════════════════════════════════════════════════

┌─────────────────────────────────────────────────────────────────────────────┐
│ PIPELINE TO WATCH                                                           │
│ ═════════════════                                                           │
│                                                                             │
│ • BARZOLVOLIMAB (anti-KIT)                                                  │
│   - 41% complete remission sustained 7 months post-treatment               │
│   - Potential for disease MODIFICATION (not just suppression)              │
│   - Phase 3 trials ongoing                                                  │
│                                                                             │
│ • REMIBRUTINIB — Phase 3 positive (REMIX-1, REMIX-2), FDA approval pending │
│                                                                             │
│ • OTHER BTK INHIBITORS                                                      │
│   - Fenebrutinib, rilzabrutinib in development                             │
│   - Oral alternatives to injectable biologics                              │
│                                                                             │
│ • HIGH-DOSE OMALIZUMAB — Research needed for comparative trials            │
└─────────────────────────────────────────────────────────────────────────────┘
```

---

## DECISION SUPPORT: BIOLOGIC SELECTION

### When to Choose OMALIZUMAB
- ✅ Prominent angioedema (HIGH-certainty data)
- ✅ Comorbid allergic asthma
- ✅ Comorbid food allergies (FDA approved)
- ✅ Need for long-term safety data (extensive experience)
- ✅ First-line biologic for most patients

### When to Choose REMIBRUTINIB
- ✅ Needle phobia (oral administration)
- ✅ Prominent angioedema (HIGH-certainty data)
- ✅ Similar efficacy to omalizumab desired
- ⚠️ Accept less long-term safety data

### When to Choose DUPILUMAB
- ✅ Comorbid atopic dermatitis
- ✅ Comorbid CRSwNP
- ✅ Comorbid eosinophilic asthma
- ❌ NOT if prominent angioedema (no data)
- ❌ NOT if angioedema is a concern

### When to Choose CYCLOSPORINE
- ✅ Biologic failure or unavailability
- ✅ Resource-limited setting
- ✅ Accept monitoring requirements
- ⚠️ May be most effective but may be most harmful
- ⚠️ Short-term use preferred

---

## EVIDENCE CERTAINTY LEGEND

| Symbol | Certainty | Meaning |
|--------|-----------|---------|
| ⊕⊕⊕⊕ | HIGH | Confident in effect estimate |
| ⊕⊕⊕○ | MODERATE | Likely close to true effect |
| ⊕⊕○○ | LOW | True effect may differ substantially |
| ⊕○○○ | VERY LOW | Very uncertain about effect |

---

*Algorithm based on AAAAI/ACAAI JTFPP Systematic Reviews 2024-2025*
*For use in Chronic Urticaria Clinical Reasoning Tool*
*Last Updated: December 2025*
